Latest News and Press Releases
Want to stay updated on the latest news?
-
VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- Li-FT Power Ltd. (“LIFT” or the “Company”) (TSXV: LIFT) (OTCQX: LIFFF) (Frankfurt: WS0) is pleased to announce the launch of the 2026...
-
New research from Momentive Software finds growth path visibility and technology efficiency are critical to workforce stability in mission-driven sector.
-
Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204
-
NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- Cointelegraph Research has released a new analysis examining how the United Nations Development Programme (UNDP) is testing blockchain technology to...
-
Nonpartisan research firm provides data for ABC News, CNN, The Associated Press, and other major networks
-
PALO ALTO, CA, March 25, 2026 (GLOBE NEWSWIRE) -- Today, the Latino Business Action Network (LBAN), in collaboration with the Stanford Graduate School of Business (GSB), released the 11th Annual...
-
NACO hosts an embargoed media briefing March 26 on its white paper and recommendations for deploying Budget 2025's $750M early-stage capital allocation.
-
VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to announce the third batch of results...
-
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist
-
Intended audience: global business, financial and trade media HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025Group net sales increased 7.3%* to EUR 27.8 billion in...